Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides one-stop CAR-T products and services for our clients. Whether you need help with CAR design and construction, T cell engineering, or anything else related to CAR-T cell development, we have the expertise and experience to get the job done.
Prostate-specific membrane antigen (PSMA) is also known as glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) or NAAG peptidase. It is a zinc metalloenzyme that is located in membranes, which mainly expressed in the tissues of the prostate epithelium, the proximal tubules of the kidney, the jejunal brush border of the small intestine, and the ganglia of the nervous system. PSMA is associated with prostate cancer as well as neovasculature of most of solid tumors.
Renal cell carcinoma
Breast cancer
Lung cancer
Colorectal cancer
Anti-PSMA CAR-T Expression Test
At Creative Biolabs, our PE-labeled PSMA, FITC-labeled PSMA, protein L and anti-Fab antibodies are effective tools for detecting anti-PSMA CAR expression on the surface of CAR-T cells. These reagents bind specifically to the scfv region of the CAR molecule, allowing for sensitive and accurate detection of CAR expression.
Fig.1 Flow cytometry analysis to evaluate CAR expression. The results show that CAR-T cells express the anti-PSMA CAR at high levels.1
Anti-PSMA CAR-T Cytokine Release Test
Our cytokine release test services utilize state-of-the-art techniques such as bead-based multiplex assay to measure the levels of key cytokines, including IL-2, IL-4, IL5, and IL-13. By accurately measuring these cytokines, we have the ability to assess the efficiency of the CAR-T treatment in targeting specific cancers and its overall immunological impact.
Fig.2 Multiplex cytokine profiling in PSMA CAR-T cells co-cultured with PC3-PSMA cells. The cytokines IL-2, IL-4, IL-5 and IL-13 are secreted at higher amounts.2
Anti-PSMA CAR-T In Vitro Cytotoxicity Assay
Anti-PSMA CAR-T therapy shows promising efficacy in patients with prostate cancer. At Creative Biolabs, we offer services to evaluate the cytotoxic activity of anti-PSMA CAR-T cells.
Fig.3 Cytolytic activity of anti-PSMA CAR-T against C4-2 cells (PSMA+) cell lines. PSMA CAR-T cells exhibited antigen-specific cytotoxicity and eliminated PSMA-positive prostate cancer cells.1
Anti-PSMA CAR-T Cell Therapy Animal Models
We provide the right animal models to study the activity and effects of the anti-PSMA CAR-T products in vivo. We use established assays and models to illuminate CAR-T biology, providing us with a deeper understanding of how the therapy works and its potential side effects.
Fig.4 Schematic of the anti-PSMA CAR-T cell therapy mouse model.2
Efficacy Test of Anti-PSMA CAR-T
Our team of experts has extensive experience in CAR-T in vivo research projects, allowing us to provide comprehensive PSMA CAR-T cell efficacy evaluation services with the best animal models.
Fig.5 In vivo potency of PSMA CAR-T cells. In vivo bioluminescence images showed treatment with PSMA CAR-T cells eliminated the tumors.2
Toxicity Evaluation Anti-PSMA CAR-T
We provide various toxicological study services including on-target and off-target toxicity, tumorigenicity studies, and so on. These assessments can characterize risk and inform clinical trial designs.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-1022-LX645 | Anti-PSMA (X10X477) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X477 | Mouse | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX646 | Anti-PSMA (X10X478) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X478 | Human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX647 | Anti-PSMA (X10X479) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X479 | Human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX648 | Anti-PSMA (X10X480) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X480 | Human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX649 | Anti-PSMA (X10X481) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X481 | Human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX650 | Anti-PSMA (X10X482) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X482 | Human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1299 | Anti-PSMA (X10X477) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X477 | Mouse | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1300 | Anti-PSMA (X10X478) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X478 | Human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1301 | Anti-PSMA (X10X479) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X479 | Human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1302 | Anti-PSMA (X10X480) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X480 | Human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1303 | Anti-PSMA (X10X481) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X481 | Human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1304 | Anti-PSMA (X10X482) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X482 | Human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1953 | Anti-PSMA (X10X477) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X477 | Mouse | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1954 | Anti-PSMA (X10X478) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X478 | Human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1955 | Anti-PSMA (X10X479) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X479 | Human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1956 | Anti-PSMA (X10X480) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X480 | Human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1957 | Anti-PSMA (X10X481) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X481 | Human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1022-LX1958 | Anti-PSMA (X10X482) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X482 | Human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
| XS-1122-YF429 | Anti-PSMA KIR CAR (scFv-KIR2DS2-DAP12, XW-429), pCDCAR1 | Human | XW-429 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF430 | Anti-PSMA KIR CAR (scFv-KIR2DS2-DAP12, XW-430), pCDCAR1 | Human | XW-430 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-0823-LX86 | Anti-hPSMA (591) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | 591 | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
